Avidity biosciences honors rare disease day®

San diego , feb. 29, 2024 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today announced its support for rare disease day®, highlighting the importance of bringing awareness to the devastating impact rare diseases have on patients, families and caregivers worldwide. "today, on rare disease day, we are proud to join the global community in raising awareness for people living with rare diseases," said sarah boyce, president and chief executive officer at avidity.
RNA Ratings Summary
RNA Quant Ranking